Lenacapavir

Gilead’s tie up with generic cos may not address HIV challenge – Times of India

Gilead’s tie up with generic cos may not address HIV challenge – Times of India

US pharma giant Gilead’s partnership with domestic generic manufacturers, aimed at enhancing access to affordable lenacapavir—a groundbreaking therapy for HIV prevention—may fall short in addressing the needs of high-incidence developing…

Continue ReadingGilead’s tie up with generic cos may not address HIV challenge – Times of India
Dr Reddy’s, Hetero ink royalty-free voluntary licencing pacts with Gilead Sciences for HIV drug Lenacapavir – Times of India

Dr Reddy’s, Hetero ink royalty-free voluntary licencing pacts with Gilead Sciences for HIV drug Lenacapavir – Times of India

Dr Reddy’s Laboratories HYDERABAD: Dr Reddy’s Laboratories and Hetero are among half a dozen generic drug makers to have entered into non-exclusive, royalty-free voluntary licencing agreements with Gilead Sciences Ireland…

Continue ReadingDr Reddy’s, Hetero ink royalty-free voluntary licencing pacts with Gilead Sciences for HIV drug Lenacapavir – Times of India